Bavarian Nordic A/S (CPH:BAVA) (OTC:BVNRY), a fully integrated biotechnology company, announced on Tuesday the initiation of the first-in-human trial of MVA-BN WEV, a prophylactic vaccine candidate against the rare, but potentially deadly illness, the equine encephalitis virus.
This programme, which is funded by the US Department of Defence (DOD) Joint Project Manager for Chemical, Biological, Radiation, and Nuclear Medical (JPM CBRN Medical) is a multi-year agreement valued up to USD36m and aims to develop a vaccine against three separate strains of the equine encephalitis virus, Eastern (EEEV), Venezuelan (VEEV) and Western (WEEV), for which there are currently no preventative vaccines available.
According to the company, this phase 1 trial will evaluate the safety, tolerability and immunogenicity of MVA-BN WEV in 45 healthy adults in three treatment groups receiving different doses of the vaccine. Topline results from the study are expected to become available in 2020.
A successful phase 1, based on demonstrating a favourable safety and immunogenicity, could lead to follow-on funding, beyond the initial contract award of USD36m, to support further preclinical, clinical development and manufacturing to support licensure in the US.
Bavarian Nordic is focused on the development of innovative therapies against infectious diseases and cancer.
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories